Human-derived Pneumocystis carinii dihydrofolate reductase (DHFR) was expressed in a Saccharomyces cerevisiae strain whose growth depends on complementation by this enzyme. We utilized a quantitative assay to measure the sensitivity of this yeast strain to DHFR inhibitors. This assay should be useful for identifying new inhibitors of human-derived P. carinii DHFR.
Human-derived Pneumocystis carinii dihydrofolate reductase (DHFR) was expressed in a Saccharomyces cerevisiae strain whose growth depends on complementation by this enzyme. We utilized a quantitative assay to measure the sensitivity of this yeast strain to DHFR inhibitors. This assay should be useful for identifying new inhibitors of human-derived P. carinii DHFR.
Current treatment of Pneumocystis carinii pneumonia (PCP)
is complicated by frequent toxic and allergic side effects, emerging drug resistance, and limited therapeutic options. There is a clear need to discover new agents against P. carinii. Dihydrofolate reductase (DHFR) is a well-described target for antimicrobial chemotherapy, and its inhibitors, like trimethoprim, pyrimethamine, and trimetrexate, are commonly used drugs for PCP therapy or prophylaxis. Genes encoding DHFR of P. carinii from various mammalian host species have been cloned (5, 8, 9) . The amino acid sequence of DHFR of human-derived P. carinii differs from that of rat-derived P. carinii by 38%, with some of the amino acid changes occurring in the active sites of the enzyme (4, 9) . Thus, the ideal target for designing potential antifolate drugs for the treatment of humans is human-derived P. carinii DHFR (9, 10). The expression of recombinant human-derived P. carinii DHFR enzyme has permitted kinetic characterization of the enzyme and reassessment of the inhibitory potency of several commonly used antifolate drugs by in vitro enzyme assays (10) . The goal of the present study was to develop a rapid, complementation-based drug screening system by using the yeast Saccharomyces cerevisiae expressing human-derived P. carinii DHFR, as has been previously reported for other organisms (3, 7, 15) .
The yeast model system used in this study was derived from an S. cerevisiae strain (TH5; Mata ura3-52 leu2-3,112 trp1 tup1 dfr1::URA3) (kindly provided by Carol Hopkins Sibley) (3) in which the endogenous DHFR gene is inactivated (6) . The human-derived P. carinii DHFR coding region was amplified by PCR from a plasmid we constructed previously (10) , cloned into an expression vector containing S. cerevisiae sequences that permit replication of the plasmid and expression of a heterologous gene in yeast (3, 13) . and transformed into TH5 cells by the lithium acetate method. The transformants were selected on plates containing tryptophan-deficient synthetic medium supplemented with 100 g of dTMP (Sigma, St. Louis, Mo.) per ml and plated on rich yeast extract-peptone-dextrose medium without dTMP to test the function of the construct (13) . TH5 yeast strains expressing rat-derived P. carinii DHFR or human DHFR have been described previously (3) .
To determine the sensitivity of the engineered yeasts to several selected antifolate drugs, assays of the concentration of the drug required to inhibit cell growth by 50% (IC 50 assays) were conducted with 1 mM sulfanilamide, as previously described (7, 13) . Each drug was tested in triplicate in at least two separate experiments. Figure 1 and Table 1 illustrate the inhibition patterns of selected DHFR inhibitors for different yeast strains. For the human-derived P. carinii DHFR yeast strain, trimethoprim and pyrimethamine were both weak inhibitors, with IC 50 s in the micromolar range; trimetrexate was about 10-fold and 40-fold more potent than trimethoprim and pyrimethamine, respectively. WR99210, a triazine compound (Jacobus Pharmaceutical Company, Princeton, N.J.), has been found to be highly effective against malaria DHFR (11, 12) but has not been tested for activity against human-derived P. carinii DHFR. WR99210 was an even more potent inhibitor, with an IC 50 in the 10 Ϫ8 M range. In comparison with the rat-derived P. carinii DHFR strain, the human-derived P. carinii DHFR strain showed very similar sensitivities to pyrimethamine and WR99210 but was about 10-fold more sensitive to both trimethoprim and trimetrexate. WR99210 exhibited excellent selectivity for both human-and rat-derived P. carinii DHFRs compared to that for human DHFR. While trimethoprim showed a relatively favorable selectivity, trimetrexate and pyrimethamine appeared not to be selective in this assay system. Table 1 shows a comparison between the IC 50 s from the yeast assay and those from an in vitro enzyme assay, based upon previously published data (for trimethoprim, pyrimethamine, and trimetrexate) or data generated in this study by using previously described methods and conditions (WR99210) (10) . Based on three experiments, the mean IC 50 (Ϯ standard deviation) of WR99210 for human-derived P. carinii DHFR was 10.0 (Ϯ1.0) nM. A comparison of the relative inhibition profiles in the yeast assay and those in the in vitro assay supports the usefulness of the yeast assay as an initial step for identifying new inhibitors of human-derived P. carinii DHFR. The yeast assay is simple, fast, and inexpensive and could readily be adapted for automation. The usefulness of this system in screening for antimicrobial drugs has been well demonstrated in previous studies (3, 7, 15) .
The IC 50 obtained by the yeast assay is the result of a complex function of the level of expression of the target enzyme in the yeast, the penetration of the drug to the cellular location of the target enzyme, and the intrinsic ability of the drug to inhibit the enzyme (3, 13) . Furthermore, the addition of 1 mM sulfanilamide in the yeast assay will also inhibit, to some extent, the growth of the yeast cells (3) . Therefore, the actual IC 50 in the yeast assay cannot be compared directly with that obtained from an in vitro assay, which reflects a direct interaction between the drug and the target enzyme under standardized conditions.
As shown in Table 1 , the absolute IC 50 s of the four drugs tested showed some differences between the two assay systems. In a given recombinant strain, enzyme expression should not account for the relative differences among drugs in the yeast assay and those in the in vitro assay, which suggests that the abilities of the drugs to penetrate the yeast cell wall may differ. Given the uncertainty about the ability of various drugs to penetrate P. carinii compared to that of yeast, application of these observations to potential therapeutic benefit in the treatment of PCP must be done cautiously.
It is of particular interest that the human-derived P. carinii DHFR yeast strain showed an approximately 10-fold increase in sensitivity to trimetrexate and trimethoprim compared to that of the rat-derived P. carinii DHFR yeast strain. Since the host yeast strains are identical, differences in penetration should not account for the relative differences among drugs demonstrated by the yeast assay and in vitro assay. Furthermore, given that the sensitivities to pyrimethamine and WR99210 were similar, it is unlikely that these differences represent differential levels of enzyme expression in the two yeast strains. Rather, as suggested by the in vitro enzyme inhibition data, this likely reflects the effects of the primary sequence differences between human-and rat-derived P. carinii DHFRs (8, 9) . DHFR inhibitors have been among the most studied classes of drugs for treatment of PCP. While animal studies (14) suggest that trimethoprim plays a minimal role in the treatment of PCP (consistent with its relatively poor inhibition seen in this and other studies), DHFR inhibitors such as trimetrexate clearly have potent anti-P. carinii activity, even as single agents (1) . The present assay should facilitate identification of additional potent and selective agents.
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